<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033254</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02461</org_study_id>
    <secondary_id>RTOG-BR-0118</secondary_id>
    <secondary_id>CDR0000069268</secondary_id>
    <secondary_id>U10CA021661</secondary_id>
    <nct_id>NCT00033254</nct_id>
  </id_info>
  <brief_title>Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases</brief_title>
  <official_title>A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC#66847) Versus Conventional Radiation Therapy for Multiple Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Randomized phase III trial to compare the effectiveness of radiation therapy with or without&#xD;
      thalidomide in treating patients who have brain metastases. Radiation therapy uses&#xD;
      high-energy x-rays to damage tumor cells. Drugs such as thalidomide may stop the growth of&#xD;
      brain metastases by stopping blood flow to the tumor. It is not yet known whether radiation&#xD;
      therapy is more effective with or without thalidomide in treating brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Compare the overall survival of patients with multiple brain metastases treated with&#xD;
      radiotherapy with or without thalidomide.&#xD;
&#xD;
      II. Compare the time to tumor progression in patients treated with these regimens.&#xD;
&#xD;
      III. Compare the time to neuro-cognitive progression in patients treated with these regimens.&#xD;
&#xD;
      IV. Compare the cause of death distribution in patients treated with these regimens.&#xD;
&#xD;
      V. Compare the frequency of toxic effects of these regimens in these patients. VI. Evaluate&#xD;
      and compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      recursive partitioning analysis class (I vs II) and planned chemotherapy after whole brain&#xD;
      irradiation (yes vs no). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      Arm I: Patients undergo radiotherapy once daily 5 days a week for 3 weeks. Arm II: Patients&#xD;
      undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients&#xD;
      receive oral thalidomide once daily.&#xD;
&#xD;
      Treatment with thalidomide continues for 2 years in the absence of disease progression or&#xD;
      unacceptable toxicity. Quality of life is assessed at baseline, at completion of&#xD;
      radiotherapy, and then every 2 months for 1 year.&#xD;
&#xD;
      Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months&#xD;
      for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 332 patients (166 per treatment arm) will be accrued for this&#xD;
      study within 14.5 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>The log-rank statistic will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>Date of randomization to documentation of progression, assessed up to 6 years</time_frame>
    <description>Cumulative incidence model will be used to analyze the data. A multivariate Cox model analysis will be performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to neuro-cognitive progression as assessed by the Mini Mental State Exam</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Cumulative incidence model will be used to analyze the data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cause of death distribution</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the Spitzer Quality of Life Index (SQLI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the SQLI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">332</enrollment>
  <condition>Tumors Metastatic to Brain</condition>
  <arm_group>
    <arm_group_label>Arm I (radiation therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo radiotherapy once daily 5 days a week for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (radiation therapy, thalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo conventional radiation therapy</description>
    <arm_group_label>Arm I (radiation therapy)</arm_group_label>
    <arm_group_label>Arm II (radiation therapy, thalidomide)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II (radiation therapy, thalidomide)</arm_group_label>
    <other_name>Kevadon</other_name>
    <other_name>Synovir</other_name>
    <other_name>THAL</other_name>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (radiation therapy)</arm_group_label>
    <arm_group_label>Arm II (radiation therapy, thalidomide)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed extracranial primary malignancy&#xD;
&#xD;
          -  Multiple brain metastases&#xD;
&#xD;
          -  At least 1 measurable brain metastasis by MRI&#xD;
&#xD;
               -  More than 4.0 cm&#xD;
&#xD;
               -  Located in midbrain or brainstem (radiosurgery ineligible)&#xD;
&#xD;
          -  Performance status - Zubrod 0-1&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 11 g/dL*&#xD;
&#xD;
          -  Hematocrit at least 35%*&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  ALT no greater than 2 times normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  BUN no greater than 25 mg/dL&#xD;
&#xD;
          -  No history of deep venous thrombosis&#xD;
&#xD;
          -  No sensory neuropathy grade 2 or greater&#xD;
&#xD;
          -  No known AIDS&#xD;
&#xD;
          -  No other major medical illness or psychiatric impairments that would preclude study&#xD;
             therapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier method of contraception during and for at&#xD;
             least 4 weeks after study&#xD;
&#xD;
          -  No prior thalidomide&#xD;
&#xD;
          -  More than 2 weeks since prior chemotherapy&#xD;
&#xD;
          -  Concurrent chemotherapy allowed if more than 6 weeks past study entry (allowed during&#xD;
             first 6 weeks of study if disease progression occurs)&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to the head or neck&#xD;
&#xD;
          -  No prior radiosurgery&#xD;
&#xD;
          -  Prior resection of brain metastases allowed&#xD;
&#xD;
          -  No concurrent anticoagulant therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Knisely</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Therapy Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiation Therapy Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

